Antidepressant of J&J leads to FDA; SCLC model discloses; Genes and macular degeneration can disclose new treatment ways

The nasal antidepressant of Johnson & Johnson leads to FDA committee

The antidepressant esketamine of Johnson & Johnson heads to FDA panel. This might be an end for the discoveries in novel therapies for the disorder. The intranasal, esketamine would be one of the first new approaches to treat the refractory major depressive disorder (MDD) if FDA gives a nod to it. This would provide a new alternative for people, who could not control symptoms though after receiving drug therapy.

New small cell lung cancer model discloses vital role of two mutated genes

Small cell lung cancer (SCLC) develops in people who smoke often and it becomes resistant to chemotherapy and radiation. The disease is contemplated to emerge from pulmonary neuroendocrine cells (PNECs). The researchers from Weill Cornell Medicine in New York have found the way of growing PNECs from human embryonic stem cells. They have figured out the two genes that are commonly mutated in SCLC.

The insights on genes and macular degeneration can disclose new treatment ways

The National Institutes of Health’s National Eye Institute (NEI) has been questing for novel ways to use the genetic underpinnings of age-related macular degeneration (AMD), a leading cause of blindness. The scientists at the NEI found 52 genetic variants that are associated with AMD. They contemplate that their findings could produce fresh ideas for disease-modifying treatments in AMD.